Economic comparison of trientine and D-penicillamine in treatment

In the treatment of hepatolenticular degeneration, a disease that requires long-term maintenance drug therapy, the economics of the drug is crucial. Trientine(Trientine) and D-penicillamine are both copper chelators. Although their mechanisms of action are slightly different, their clinical efficacy is relatively similar. At the price level, however, there are significant differences between the two.

The original drug of Trientine has been on the market for many years in Europe and the United States, especially the Trientine salt drug produced in Germany, and its price is generally high. According to overseas market data, the price of each box of 200mg*100 tablets of trientine may exceed RMB 40,000. The reasons for the high price include not only R&D costs and patent protection, but also multiple factors such as supply chain, market access and manufacturing standards.

In comparison,D-penicillamine is relatively affordable. Although some countries classify it as an old or orphan drug, there are still a large number of generic drugs available. Countries represented by India or Bangladesh produce generic versions of D-penicillamine at a more advantageous price, usually ranging from hundreds to thousands of yuan, which is far lower than the market price of trientine.

However, the cost of treating adverse reactions also needs to be weighed in the economic evaluation. D-penicillamine has more significant side effects and may cause severe rash, kidney damage, leukopenia, etc., causing patients to have to undergo more frequent clinical monitoring and deal with related complications. Trientine is better tolerated, and although it is expensive, it may reduce the additional medical burden during treatment.

Therefore, considering the total cost, if patients can tolerate it wellD-penicillamine will undoubtedly be more cost-effective. However, in patients who are sensitive to drugs and cannot tolerate side effects, the clinical value of trientine is more obvious. In reality, economics has a great impact on patients' drug compliance. If trientine generics or low-priced original drugs can be widely promoted, it will bring long-term benefits to more patients with rare diseases.

Reference materials:https://www.cufence.com/